US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US8143283B1
(en)
*
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
US5629327A
(en)
*
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US6805865B1
(en)
|
1993-05-27 |
2004-10-19 |
Entremed, Inc. |
Compositions and methods for treating cancer and hyperproliferative disorders
|
US20040248799A1
(en)
*
|
1993-05-27 |
2004-12-09 |
Holaday John W. |
Compositions and methods for treating cancer and hyperproliferative disorders
|
DE4422237A1
(en)
*
|
1994-06-24 |
1996-01-04 |
Gruenenthal Gmbh |
Use of lactam compounds as active pharmaceutical ingredients
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US6358735B1
(en)
|
1995-06-30 |
2002-03-19 |
University Of Kansas Medical Center |
Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
|
US6440729B1
(en)
*
|
1995-06-30 |
2002-08-27 |
University Of Kansas Medical Center |
Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
|
US6518281B2
(en)
*
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
JP3263598B2
(en)
*
|
1995-11-01 |
2002-03-04 |
有限会社ドット |
Bioactive peptide composition for nasal absorption
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
US5798368A
(en)
*
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
EP2177517B1
(en)
*
|
1996-07-24 |
2011-10-26 |
Celgene Corporation |
Amino substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimide for reducing TNF alpha levels
|
ES2529190T3
(en)
*
|
1996-07-24 |
2015-02-17 |
Celgene Corporation |
2- (2,6-Dioxopiperidin-3-yl) -amino-substituted phthalimides to reduce TNF-alpha levels
|
US5955496A
(en)
*
|
1996-08-13 |
1999-09-21 |
The Regents Of The University Of California |
Dihydroxy-oxy-eicosadienoates
|
DK1586322T3
(en)
*
|
1996-11-05 |
2008-12-01 |
Childrens Medical Center |
Compositions containing thalidomide and dextamethasone for the treatment of cancer
|
US5981508A
(en)
|
1997-01-29 |
1999-11-09 |
Vanderbilt University |
Facilitation of repair of neural injury with CM101/GBS toxin
|
US5858991A
(en)
*
|
1997-01-29 |
1999-01-12 |
Vanderbilt University |
Facilitation of wound healing with CM101/GBS toxin
|
US6028060A
(en)
*
|
1997-01-29 |
2000-02-22 |
Vanderbilt University |
Treatment of chronic inflammatory diseases with CM101/GBS toxin
|
US6670337B1
(en)
|
1998-01-29 |
2003-12-30 |
Yeda Reaearch And Development Co., Ltd. |
Facilitation of wound healing with CM101/GBS toxin
|
US6593291B1
(en)
|
1997-02-06 |
2003-07-15 |
Entremed, Inc. |
Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
|
US5994388A
(en)
*
|
1997-03-18 |
1999-11-30 |
The Children's Medical Center Corporation |
Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
|
US6265388B1
(en)
|
1997-03-21 |
2001-07-24 |
President And Fellows Of Harvard College |
Antisense inhibition of angiogenin expression
|
US6174695B1
(en)
|
1997-08-12 |
2001-01-16 |
The Regents Of The University Of California |
Epoxide hydrolase inhibitor methods
|
EP1017389A1
(en)
|
1997-08-25 |
2000-07-12 |
Harold Brem |
Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
|
EP1710242A1
(en)
*
|
1997-11-18 |
2006-10-11 |
Celgene Corporation |
Substituted 2-(2,6-Dioxo-3-Fluoropiperidine-3-YL)-Isoindolines and their use to reduce TNF-alpha levels
|
US5955476A
(en)
*
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
NZ506432A
(en)
*
|
1998-03-16 |
2003-08-29 |
Celgene Corp |
2-(2,6-dioxopiperidin-3-yl) isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
CA2331620A1
(en)
|
1998-05-11 |
1999-11-18 |
The Endowment For Research In Human Biology, Inc. |
Use of neomycin for treating angiogenesis-related diseases
|
AU749356B2
(en)
*
|
1998-05-11 |
2002-06-27 |
Children's Medical Center Corporation |
Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
|
US8197430B1
(en)
*
|
1998-05-22 |
2012-06-12 |
Biopheresis Technologies, Inc. |
Method and system to remove cytokine inhibitor in patients
|
US6620382B1
(en)
*
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
US8609614B2
(en)
|
1998-07-22 |
2013-12-17 |
Vanderbilt University |
GBS toxin receptor compositions and methods of use
|
US6576613B1
(en)
*
|
1998-07-24 |
2003-06-10 |
Corvas International, Inc. |
Title inhibitors of urokinase
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US6537554B1
(en)
|
1998-09-10 |
2003-03-25 |
Curagen Corporation |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
AU5991699A
(en)
|
1998-09-21 |
2000-04-10 |
Biochem Pharma Inc. |
Quinolizinones as integrin inhibitors
|
US6231889B1
(en)
|
1998-09-21 |
2001-05-15 |
Chronorx, Llc |
Unit dosage forms for the treatment of herpes simplex
|
US6596690B2
(en)
|
1998-10-06 |
2003-07-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vasostatin as marrow protectant
|
FR2784580B1
(en)
*
|
1998-10-16 |
2004-06-25 |
Biosepra Inc |
POLYVINYL-ALCOHOL MICROSPHERES AND METHODS OF MAKING THE SAME
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US7238711B1
(en)
|
1999-03-17 |
2007-07-03 |
Cambridge University Technical Services Ltd. |
Compounds and methods to inhibit or augment an inflammatory response
|
WO2000041547A2
(en)
*
|
1999-01-13 |
2000-07-20 |
The Rockefeller University |
Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
|
CN1342146A
(en)
*
|
1999-03-18 |
2002-03-27 |
塞尔基因公司 |
Substituted 1-oxo-and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
DK1040838T3
(en)
|
1999-03-31 |
2003-05-26 |
Gruenenthal Gmbh |
Stable aqueous solution of 3- (1-oxo-1,3-dihydroisoindol-2-yl) piperidine-2,6-dione
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6468990B1
(en)
*
|
1999-05-17 |
2002-10-22 |
Queen's University At Kingston |
Method of inhibiting binding of nerve growth factor to p75 NTR receptor
|
US6673843B2
(en)
*
|
1999-06-30 |
2004-01-06 |
Emory University |
Curcumin and curcuminoid inhibition of angiogenesis
|
US6916843B1
(en)
*
|
1999-08-11 |
2005-07-12 |
The United States Of America As Represented By The Department Of Health And Human Services |
Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids
|
US7087592B1
(en)
|
1999-08-23 |
2006-08-08 |
Entre Med, Inc. |
Compositions comprising purified 2-methoxyestradiol and methods of producing same
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
ES2356369T3
(en)
|
1999-11-10 |
2011-04-07 |
Biopheresis Technologies, Inc. |
METHOD AND SYSTEM OF ELIMINATING THE CYTOKIN INHIBITOR IN PATIENTS.
|
US6204270B1
(en)
*
|
1999-11-12 |
2001-03-20 |
Eyal S. Ron |
Ophthalmic and mucosal preparations
|
JP2003514524A
(en)
|
1999-11-18 |
2003-04-22 |
コルバス・インターナショナル・インコーポレイテッド |
Nucleic acid encoding an endoceliase, endotheliase and uses thereof
|
US6379708B1
(en)
*
|
1999-11-20 |
2002-04-30 |
Cytologic, Llc |
Method for enhancing immune responses in mammals
|
WO2001041755A2
(en)
*
|
1999-12-02 |
2001-06-14 |
The Regents Of The University Of Michigan |
Topical compositions comprising thalidomide for the treatment of inflammatory diseases
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6699899B1
(en)
*
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
US7700341B2
(en)
*
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
CN1121218C
(en)
*
|
2000-03-08 |
2003-09-17 |
台湾东洋药品工业股份有限公司 |
Medicine composition for treating hepatocellular carcinoma
|
US20030212022A1
(en)
*
|
2001-03-23 |
2003-11-13 |
Jean-Marie Vogel |
Compositions and methods for gene therapy
|
DE60130743T2
(en)
*
|
2000-03-24 |
2008-07-17 |
Biosphere Medical, Inc., Rockland |
MICROBALLS FOR ACTIVE EMBOLIZATION
|
MXPA02009665A
(en)
*
|
2000-03-31 |
2005-09-08 |
Celgene Corp |
Inhibition of cyclooxygenase 2 activity.
|
NZ522766A
(en)
|
2000-05-15 |
2005-09-30 |
Celgene Corp |
Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects
|
ES2258084T3
(en)
|
2000-05-15 |
2006-08-16 |
Celgene Corporation |
COMPOSITIONS FOR THE TREATMENT OF CANCER THAT INCLUDE AN INHIBITOR OF TOPOISOMERASA AND TALIDOMIDA.
|
US20030104573A1
(en)
*
|
2000-09-11 |
2003-06-05 |
Shimkets Richard A. |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
WO2002064083A2
(en)
*
|
2000-11-30 |
2002-08-22 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
US20040121945A1
(en)
*
|
2000-12-15 |
2004-06-24 |
Hong Liang |
Compositions and methods for inhibiting endothelial cell proliferation
|
EP1226824A1
(en)
*
|
2001-01-24 |
2002-07-31 |
TTY Biopharm Company Limited |
Use of thalidomide for the treatment of hepatocellular carcinoma
|
US6632835B2
(en)
|
2001-02-22 |
2003-10-14 |
Nanodesign Inc. |
Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
|
EP1389203B8
(en)
*
|
2001-02-27 |
2010-03-10 |
The Governement of the United States of America, represented by The Secretary Department of Health and Human services |
Analogs of thalidomide as angiogenesis inhibitors
|
WO2002086078A2
(en)
*
|
2001-04-23 |
2002-10-31 |
University Of Virginia Patent Foundation |
Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
|
AU2002329643B2
(en)
*
|
2001-07-27 |
2006-11-16 |
University Of Kansas Medical Center |
Crystallized structure of type IV collagen NC1 domain hexamer
|
ES2325916T3
(en)
*
|
2001-08-06 |
2009-09-24 |
The Children's Medical Center Corporation |
ANTIANGIOGENIC ACTIVITY OF TALIDOMIDE ANALOGS REPLACED WITH NITROGEN.
|
GB0125659D0
(en)
*
|
2001-10-25 |
2001-12-19 |
Ssl Int Plc |
Spermicides
|
AU2002357004A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
US20030139469A1
(en)
*
|
2002-01-23 |
2003-07-24 |
The Regents Of The University Of California |
Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
|
US7939497B2
(en)
*
|
2002-03-08 |
2011-05-10 |
Shanghai Institutes For Biological Sciences, Cas |
Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
|
WO2003075847A2
(en)
*
|
2002-03-08 |
2003-09-18 |
Emory University |
NOVEL CURCUMINOID-FACTOR VIIa CONSTRUCTS AS SUPPRESSORS OF TUMOR GROWTH AND ANGIOGENESIS
|
WO2003086283A2
(en)
*
|
2002-04-09 |
2003-10-23 |
Greenville Hospital System |
Metastasis modulating activity of highly sulfated oligosaccharides
|
NZ536908A
(en)
*
|
2002-05-17 |
2008-09-26 |
Celgene Corp |
Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
EP2272512A1
(en)
|
2002-05-17 |
2011-01-12 |
Celgene Corporation |
Pharmaceutical compositions for treating cancer
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
WO2004002418A2
(en)
*
|
2002-06-26 |
2004-01-08 |
Entremed, Inc |
Compositions and methods comprising protein activated receptor antagonists
|
US20040175378A1
(en)
|
2002-07-15 |
2004-09-09 |
Board Of Regents, The University Of Texas System |
Selected antibody compositions and methods for binding to aminophospholipids
|
WO2004009030A2
(en)
*
|
2002-07-22 |
2004-01-29 |
Chemgenex Pharmaceuticals Limited |
Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
|
KR20050025976A
(en)
*
|
2002-07-23 |
2005-03-14 |
더 리젠츠 오브 더 유니버시티 오브 미시건 |
Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
WO2004034962A2
(en)
*
|
2002-10-15 |
2004-04-29 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
CA2504024A1
(en)
*
|
2002-10-31 |
2004-05-21 |
Celgene Corporation |
Composition for the treatment of macular degeneration
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
CA2505131A1
(en)
|
2002-11-06 |
2004-05-27 |
Celgene Corporation |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
BR0316206A
(en)
*
|
2002-11-12 |
2005-09-27 |
Alcon Inc |
Use of histone deacetylase inhibitors for the treatment of neovascular or edematous eye disorders
|
US7230012B2
(en)
*
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
US9006267B2
(en)
*
|
2002-11-14 |
2015-04-14 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
US8431396B2
(en)
|
2003-03-21 |
2013-04-30 |
The Cleveland Clinic Foundation |
Anti-angiogenic peptides
|
US7868011B2
(en)
*
|
2003-04-09 |
2011-01-11 |
General Atomics |
Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
|
US7517887B2
(en)
*
|
2003-04-09 |
2009-04-14 |
General Atomics |
Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
|
US7196093B2
(en)
*
|
2003-04-09 |
2007-03-27 |
General Atomics |
Reversible inhibitors of SAH hydrolase and uses thereof
|
DE10323898A1
(en)
|
2003-05-26 |
2004-12-23 |
Wilex Ag |
Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
|
CA2527074A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Entremed, Inc. |
Antiangiogenic agents
|
WO2005016326A2
(en)
*
|
2003-07-11 |
2005-02-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
TW201319088A
(en)
|
2003-07-18 |
2013-05-16 |
Amgen Inc |
Specific binding agents to hepatocyte growth factor
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
SG133603A1
(en)
|
2003-09-17 |
2007-07-30 |
Us Gov Health & Human Serv |
Thalidomide analogs as tnf-alpha modulators
|
US20080027113A1
(en)
*
|
2003-09-23 |
2008-01-31 |
Zeldis Jerome B |
Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
AP2006003637A0
(en)
|
2003-11-06 |
2006-06-30 |
Celgene Corp |
Methods and compositions using thalidomide for thetreatment and management of cancers and other diseases
|
WO2005046686A1
(en)
*
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
WO2005055929A2
(en)
*
|
2003-12-02 |
2005-06-23 |
Celgene Corporation |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
US7430276B2
(en)
*
|
2004-02-25 |
2008-09-30 |
Nanodynamics-88 |
Low dose X-ray mammography method
|
WO2005089256A2
(en)
*
|
2004-03-12 |
2005-09-29 |
Entremed, Inc. |
Antiangiogenic agents
|
KR101224262B1
(en)
*
|
2004-03-22 |
2013-01-21 |
셀진 코포레이션 |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
BRPI0418743A
(en)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit
|
BRPI0418742A
(en)
*
|
2004-04-14 |
2007-09-11 |
Celgene Corp |
methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit
|
EP1755599A4
(en)
*
|
2004-04-23 |
2007-06-06 |
Celgene Corp |
Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
|
CN101163489A
(en)
*
|
2004-04-23 |
2008-04-16 |
细胞基因公司 |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
AU2005240082B2
(en)
*
|
2004-04-30 |
2009-07-23 |
Innatus Corporation |
Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
|
US7273890B1
(en)
*
|
2004-06-08 |
2007-09-25 |
Sagittarius Life Science Corp. |
ST104P, an anti-angiogenic agent
|
JP2008510726A
(en)
*
|
2004-08-20 |
2008-04-10 |
エントレメッド インコーポレイテッド |
Compositions and methods comprising proteinase activated receptor antagonists
|
EP2479172B1
(en)
*
|
2004-09-03 |
2013-10-09 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
|
JP2008518924A
(en)
*
|
2004-10-28 |
2008-06-05 |
セルジーン・コーポレーション |
Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
|
ZA200704890B
(en)
*
|
2004-11-23 |
2008-09-25 |
Celgene Corp |
Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
|
CN104815331A
(en)
|
2005-05-09 |
2015-08-05 |
生物领域医疗公司 |
Compositions and methods using microspheres and non-ionic contrast agents
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
US20080167272A1
(en)
*
|
2005-06-16 |
2008-07-10 |
Auckland Uniservices Limited |
Thalidomide metabolites and methods of use
|
SI2380887T1
(en)
|
2005-06-30 |
2013-12-31 |
Celgene Corporation |
Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
|
WO2007009001A1
(en)
*
|
2005-07-12 |
2007-01-18 |
The Regents Of The University Of California |
Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to alleviate eye disorders
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070065514A1
(en)
*
|
2005-09-22 |
2007-03-22 |
Howell Mark D |
Method for enhancing immune responses in mammals
|
CN1939922B
(en)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor
|
EP1940410A1
(en)
*
|
2005-10-14 |
2008-07-09 |
F.Hoffmann-La Roche Ag |
Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo [3, 4.-b] [1, 4] benzodiazepine
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
WO2007090127A2
(en)
|
2006-01-30 |
2007-08-09 |
Surgica Corporation |
Compressible intravascular embolization particles and related methods and delivery systems
|
WO2007090130A2
(en)
*
|
2006-01-30 |
2007-08-09 |
Surgica Corporation |
Porous intravascular embolization particles and related methods
|
AU2007227256B2
(en)
*
|
2006-03-20 |
2012-10-04 |
Entremed, Inc. |
Disease modifying anti-arthritic activity of 2-methoxyestradiol
|
US20070226632A1
(en)
*
|
2006-03-21 |
2007-09-27 |
Nokia Corporation |
Method, electronic device and computer program product for enhancing contact list functionality
|
EP2004614B1
(en)
*
|
2006-04-13 |
2016-10-19 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Tetrahalogenated compounds useful as inhibitors of angiogenesis
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
AU2007267928A1
(en)
*
|
2006-05-26 |
2007-12-06 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds in combination therapy
|
US20080051431A1
(en)
*
|
2006-05-26 |
2008-02-28 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds in combination therapy
|
WO2008007979A1
(en)
*
|
2006-07-12 |
2008-01-17 |
Auckland Uniservices Limited |
(2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
|
PE20121506A1
(en)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
WO2008011513A2
(en)
|
2006-07-19 |
2008-01-24 |
The Cleveland Clinic Foundation |
Compounds and methods of modulating angiogenesis
|
CL2007002218A1
(en)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
USE OF 3- (4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL) -PIPERIDINE 2,6-DIONA FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF LAYER CELL LYMPHOMA.
|
CN101138634A
(en)
|
2006-09-07 |
2008-03-12 |
于保法 |
Composition for treating tumour
|
US20080075690A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Mark Douglas Howell |
Method for enhancing immune responses in mammals
|
EP2114898A2
(en)
|
2007-02-16 |
2009-11-11 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
|
JP5550546B2
(en)
*
|
2007-04-13 |
2014-07-16 |
ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド |
Oral cephalotaxin dosage form
|
WO2009020590A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
CL2008002444A1
(en)
|
2007-08-21 |
2009-09-04 |
Amgen Inc |
Antibody or fragment thereof that binds to human c-fms protein; nucleic acid molecule that encodes it; vector and host cell; production method; pharmaceutical composition comprising it; and its use to treat or prevent a condition associated with c-fms in a patient.
|
JP2010539245A
(en)
|
2007-09-14 |
2010-12-16 |
日東電工株式会社 |
Drug carrier
|
US11331294B2
(en)
|
2007-09-26 |
2022-05-17 |
Indiana University Research And Technology Corporation |
Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
|
KR101572688B1
(en)
*
|
2007-09-26 |
2015-11-27 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of cancer and angiogenesis
|
JP5809415B2
(en)
|
2007-11-09 |
2015-11-10 |
ペレグリン ファーマシューティカルズ,インコーポレーテッド |
Compositions and methods of anti-VEGF antibodies
|
US20090137631A1
(en)
*
|
2007-11-22 |
2009-05-28 |
National Yang-Ming University |
Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
|
EP2294184A4
(en)
|
2008-06-30 |
2013-03-06 |
Mesoblast Inc |
Treatment of eye diseases and excessive neovascularization using a combined therapy
|
CA2737146A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
US20110212179A1
(en)
*
|
2008-10-30 |
2011-09-01 |
David Liu |
Micro-spherical porous biocompatible scaffolds and methods and apparatus for fabricating same
|
DK3351240T3
(en)
|
2009-05-19 |
2019-06-17 |
Celgene Corp |
FORMULATIONS OF 4-AMINO-2- (2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLIN-1,3-DION
|
US20120134969A1
(en)
|
2009-05-25 |
2012-05-31 |
Hiroshi Handa |
Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
|
GB0914330D0
(en)
|
2009-08-17 |
2009-09-30 |
Univ Dublin City |
A method of predicting response to thalidomide in multiple myeloma patients
|
WO2011038139A1
(en)
|
2009-09-23 |
2011-03-31 |
Amgen Inc. |
Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
WO2012079088A2
(en)
|
2010-12-10 |
2012-06-14 |
The Johns Hopkins University |
Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
|
US8623885B2
(en)
|
2011-03-23 |
2014-01-07 |
Amgen Inc. |
Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
|
KR20140024914A
(en)
|
2011-04-29 |
2014-03-03 |
셀진 코포레이션 |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
JP6069312B2
(en)
|
2011-06-29 |
2017-02-01 |
アムジェン インコーポレイテッド |
Predictive biomarkers of survival in the treatment of renal cell carcinoma
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
US20130058926A1
(en)
*
|
2011-08-30 |
2013-03-07 |
Shiseido Company, Ltd. |
Method for alleviating and/or preventing skin reddening
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
EP2817300B1
(en)
|
2012-02-21 |
2018-04-25 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
AR090263A1
(en)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
|
CA2877736C
(en)
*
|
2012-06-29 |
2021-12-07 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
EP2954330A4
(en)
|
2013-02-08 |
2016-08-31 |
Inst Myeloma & Bone Cancer Res |
Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
|
BR112015019509A2
(en)
|
2013-02-13 |
2017-07-18 |
Cartiheal 2009 Ltd |
solid substrates to attenuate or prevent tissue and cell adhesion and vascularization
|
EP2970372B1
(en)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
US8906951B1
(en)
|
2013-06-24 |
2014-12-09 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
US9198898B2
(en)
|
2013-06-24 |
2015-12-01 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
WO2015116802A1
(en)
|
2014-01-29 |
2015-08-06 |
Otsuka Pharmaceutical Co., Ltd. |
Device-based risk management of a therapeutic
|
EP4233870A3
(en)
|
2014-05-28 |
2024-01-24 |
Onco Tracker, Inc. |
Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
|
ES2843973T3
(en)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Compositions and methods to induce conformational changes in cereblon and other E3 ubiquitin ligases
|
WO2016029004A1
(en)
|
2014-08-22 |
2016-02-25 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
AU2015341301B2
(en)
|
2014-10-30 |
2019-05-16 |
Kangpu Biopharmaceuticals, Ltd. |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
WO2016086070A1
(en)
|
2014-11-26 |
2016-06-02 |
Baofa Yu |
Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy
|
SI3313818T1
(en)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
WO2016209972A1
(en)
|
2015-06-26 |
2016-12-29 |
Amgen Inc. |
Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
|
AU2016297793A1
(en)
|
2015-07-24 |
2018-02-08 |
Oncotracker, Inc. |
Gamma secretase modulators for the treatment of immune system dysfunction
|
CA3000661C
(en)
|
2015-09-30 |
2024-04-02 |
Nigel H. Greig |
Thalidomide analogs and methods of use
|
CN114948963A
(en)
|
2015-10-21 |
2022-08-30 |
大冢制药株式会社 |
Protein kinase inhibitor benzolactam compounds
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
ES2898329T3
(en)
|
2016-01-12 |
2022-03-07 |
Oncotracker Inc |
Improved methods for monitoring the immune status of a subject
|
MY195432A
(en)
*
|
2016-03-31 |
2023-01-20 |
Omeros Corp |
Methods For Inhibiting Angiogenesis In A Subject In Need Thereof
|
CN110290807A
(en)
|
2016-12-03 |
2019-09-27 |
朱诺治疗学股份有限公司 |
The method for determining CAR-T cell administration
|
WO2018102786A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
DK3558955T3
(en)
|
2016-12-22 |
2021-10-25 |
Amgen Inc |
BENZISOTHIAZOLE, ISOTHIAZOLO [3,4-B] PYRIDINE-, QUINAZOLINE-, PHTHALAZINE-, PYRIDO [2,3-D] PYRIDAZINE- AND PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES LIKE KRAS-GANDERHINH -, PANCREAS OR COLOR RECTAL CANCER
|
EP3576726A1
(en)
|
2017-02-06 |
2019-12-11 |
Massachusetts Institute Of Technology |
Methods and products related to glutaminase inhibitors
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
IL310031A
(en)
|
2017-05-01 |
2024-03-01 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
JOP20190272A1
(en)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
MX2019014268A
(en)
|
2017-06-02 |
2020-08-03 |
Juno Therapeutics Inc |
Articles of manufacture and methods for treatment using adoptive cell therapy.
|
EP3639028A4
(en)
|
2017-06-13 |
2021-04-14 |
Inc. Onco Tracker |
Diagnostic, prognostic, and monitoring methods for solid tumor cancers
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
US10513515B2
(en)
|
2017-08-25 |
2019-12-24 |
Biotheryx, Inc. |
Ether compounds and uses thereof
|
CN116003405A
(en)
|
2017-09-08 |
2023-04-25 |
美国安进公司 |
Inhibitors of KRAS G12C and methods of use thereof
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
MA51210A
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
|
KR20200110745A
(en)
|
2017-12-15 |
2020-09-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-CCT5 binding molecule and method of use thereof
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
WO2019210080A1
(en)
*
|
2018-04-25 |
2019-10-31 |
The Regents Of The University Of California |
Methods and compositions for skeletal and neurological disorders
|
AU2019262589B2
(en)
|
2018-05-04 |
2022-07-07 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MA52496A
(en)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
EP3830093A1
(en)
|
2018-07-27 |
2021-06-09 |
Biotheryx, Inc. |
Bifunctional compounds as cdk modulators
|
AU2019377854A1
(en)
|
2018-11-08 |
2021-05-27 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and T cell modulation
|
JP2020090482A
(en)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Improved synthesis of key intermediate of kras g12c inhibitor compound
|
AU2019381827A1
(en)
|
2018-11-16 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods of dosing engineered T cells for the treatment of B cell malignancies
|
EP3883565A1
(en)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7377679B2
(en)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
|
SG11202105502RA
(en)
|
2018-11-30 |
2021-06-29 |
Juno Therapeutics Inc |
Methods for treatment using adoptive cell therapy
|
JP2022513971A
(en)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Heteroarylamide useful as a KIF18A inhibitor
|
IL283639B1
(en)
|
2018-12-20 |
2024-02-01 |
Amgen Inc |
Kif18a inhibitors
|
JP2022513967A
(en)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Heteroarylamide useful as a KIF18A inhibitor
|
ES2953821T3
(en)
|
2018-12-20 |
2023-11-16 |
Amgen Inc |
KIF18A inhibitors
|
KR20210122272A
(en)
|
2019-01-29 |
2021-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase-like orphan receptor 1 (ROR1)
|
KR20210146287A
(en)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
Bicyclic heteroaryl compounds and uses thereof
|
WO2020180770A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
MX2021014126A
(en)
|
2019-05-21 |
2022-01-04 |
Amgen Inc |
Solid state forms.
|
EP4007638A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Pyridine derivatives as kif18a inhibitors
|
CN114302880A
(en)
|
2019-08-02 |
2022-04-08 |
美国安进公司 |
KIF18A inhibitors
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020369569A1
(en)
|
2019-10-24 |
2022-04-14 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
TW202132314A
(en)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras inhibitors
|
WO2021091967A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2021092115A1
(en)
|
2019-11-08 |
2021-05-14 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
EP4058432A1
(en)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
JP2023505100A
(en)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
Covalent RAS inhibitors and uses thereof
|
KR20220124768A
(en)
|
2020-01-07 |
2022-09-14 |
레볼루션 메디슨즈, 인크. |
SHP2 inhibitor administration and cancer treatment method
|
WO2021222150A2
(en)
|
2020-04-28 |
2021-11-04 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|
AU2021293228A1
(en)
|
2020-06-18 |
2023-02-09 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
|
KR20230081726A
(en)
|
2020-09-03 |
2023-06-07 |
레볼루션 메디슨즈, 인크. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
MX2023003060A
(en)
|
2020-09-15 |
2023-04-05 |
Revolution Medicines Inc |
Indole derivatives as ras inhibitors in the treatment of cancer.
|
AR124449A1
(en)
|
2020-12-22 |
2023-03-29 |
Qilu Regor Therapeutics Inc |
SOS1 INHIBITORS AND USES THEREOF
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
US20220396589A1
(en)
|
2021-05-05 |
2022-12-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AR125782A1
(en)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
RAS INHIBITORS
|
AR127308A1
(en)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
RAS INHIBITORS
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|